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| INTRODUCTION
The overall mortality and morbidity after liver transplantation (LT) have decreased significantly from the start of the programs in all transplant centers. The current recipient survival rates in Nordic countries are approximately 91% at 1 year and 80% at 5 years. 1 The reduction in mortality has occurred mainly during the first posttransplant year. In contrast, survival rates beyond this time point have not significantly improved over the last decades. [2] [3] [4] [5] Cancer is a leading cause of late death after LT. 2, [6] [7] [8] The immunosuppressive medication is a key factor driving the increased risk for cancer posttransplantation. [9] [10] [11] [12] In immunosuppressed patients, cancers tend to be more advanced at diagnosis and at young ages, though the age distribution of people with cancer reflects, in part, the ages at which they received LT. 13, 14 The gradually increasing age of LT recipients 5 is also a risk factor for cancer. 9, 15 Other risk factors include sun exposure, smoking, and hepatitis C infection. [15] [16] [17] [18] Cancer risk is increased particularly in alcoholic cirrhosis and primary sclerosing cholangitis (PSC) patients. 15, [18] [19] [20] With the growing LT activity, it is important to evaluate possible changes in post-LT complications. Little is known about changes over time in cancer risk after LT.
A proper way to analyze true cancer risk is to calculate the relationship between observed and expected cancer incidence (ie standardized incidence ratio [SIR] ), stratified by sex, age, and calendar period. All of the Nordic countries have a compulsory and comprehensive cancer registry based on individual social security number. The cancer registries can be linked with transplantation registries using the personal number, thus achieving highly reliable data on cancer incidence and SIRs in the transplantation population.
The aim of the present study was to link all Nordic national transplant registries with the cancer registry in each country and to compare overall and site-specific cancer incidence of LT patients with the background population, according to decade and indication of the LT.
| MATERIALS AND METHODS
Patient data were derived from the Nordic LT Registry, which includes records of all LTs in Finland, Sweden, Norway, and Denmark since 1982. Nordic LT Registry data are maintained by the Nordic Liver
Transplant Group and stored at Scandiatransplant in Aarhus University
Hospital, Denmark. Scandiatransplant is the official organ exchange organization in the Nordic countries. The study protocol was approved by the appropriate institutional review boards in each country.
The study included all patients (n = 4246) ≥17 years of age who underwent LT between 1982 and 2013. The data comprised date of birth, sex, date of LT and re-LT, indication for LT, country of LT, and immunosuppression drugs used during the first month. Linking by the personal identity codes to the national population registers data on vital status were obtained for every cohort member.
We followed up for cancers through linkage by the personal identity code to the respective national cancer registries. Follow-up for cancer started at the date of the first transplant and ended at death or immigration, or at study closure on December 31, 2013.
The cancer registration system in the Nordic countries is virtually complete 21 and the computerized record linkage procedure precise,
22
thus providing unbiased control data and accurate comparisons for the study. Basal cell carcinoma was excluded from this study.
| Statistical analysis
The numbers of cancer cases and person-years at risk were counted by 5-year age groups, separately for each calendar year and country. The expected numbers of cases for all cancers combined and for specific cancer types were calculated by multiplying the number of person-years in each gender and age group by the corresponding cancer incidence rate in the respective country during the period of observation.
The SIR was calculated by dividing the observed number of cases by the expected number. The 95% confidence intervals (CI) for the SIR were based on the assumption that the number of observed cases followed a Poisson distribution.
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Liver cancers recorded in cancer registries within 6 months from LT were considered as pre-LT cancers that had been confirmed with a delay (n = 122), and were thus excluded from the de novo post-LT cancer counts. In practice, observed and expected numbers of liver cancers during the first 6 months of follow-up were excluded. For the same reason, biliary cancers registered within 6 months from LT (n = 4)
were considered pre-LT cancers among PSC patients. In SIR compari- tacrolimus-than cyclosporine-based medication and less use of azathioprine in contrast to mycophenolate.
During follow-up, 461 primary cancers were observed in 424 patients. The cumulative incidence of posttransplant primary cancer was 1% at 1 year, 3% at 3 years, 5% at 5 years, 11% at 10 years, and 22%
at 20 years ( Figure 1 ). The respective cumulative incidence rates for all primary cancers except nonmelanoma skin cancer were 1%, 3%, 4%, 9%, and 15% ( Figure 1 ).
The overall SIR was 2.22 (95% CI, 2.02%-2.43%), and the SIR for all cancer types excluding nonmelanoma skin cancer was 1.69 (95% CI, 1.51%-1.88%). In the total cohort of liver transplanted patients, out of 41 cancer types studied, significantly elevated SIRs were seen for 12 cancer types, whereas the SIR for prostate cancer was significantly reduced ( Table 2 ).
SIRs were similar for male and female patients and generally decreased with increasing age (Table 3) . SIRs were generally stable or decreased with time since LT, but the SIRs for pancreatic and kidney cancers increased with increasing time after LT.
The highest overall SIRs were observed in Denmark (Table 3) , and
Danish LT patients had the highest SIRs for nonmelanoma skin cancers, liver, and lung cancers. Finnish LT patients showed the highest SIRs for non-Hodgkin lymphoma and pancreatic cancer.
| Cancer risk by liver disease etiology
Cancer risk profile varied by liver-disease etiology (Table 3) 
| Temporal changes in SIRs
SIRs for cancers occurring within 10 years from LT decreased over Table 3 and Supplemental Table S1 ). Such a time-period-dependent decrease was almost universal for the various cancer types, but most striking for nonmelanoma skin cancer, non-Hodgkin lymphoma, and liver cancer ( Figure 2 and Table 3 ). Furthermore, the timeperiod-dependent decrease in overall cancer SIRs occurred across gender-, age-, and etiology groups ( Figure 2 and Supplemental Table   S1 ). Average follow-up according to transplant decade (with follow-up truncated at 10 years) was 5.4 years for the 1980s, 7.0 years for the 1990s, and 4.8 years for 2000s (P among groups <.001).
| Colorectal cancer
As an elevated colorectal cancer risk seemed to affect the PSC group exclusively, we performed further subgroup analyses. Among all non-PSC patients combined, we observed no elevated colorectal cancer risk overall (SIR 1.03, 95% CI, 0.65%-1.56%) or in subgroups stratified by gender, age, or time since LT (data not shown). In the PSC group, SIRs for colorectal cancer were fairly similar among males (SIR 3.74, 95% CI, 1.61%-7.37%) and females (SIR 4.82, 95% CI, 1.30%-12.3%), and within 10 years from LT (SIR 4.27, 95% CI, 1.95%-8.10%) compared to after 10 years (SIR 3.19, 95% CI, 0.64%-9.32%).
Of all primary post-LT colorectal cancers, 24 (71%) occurred within 10 years from LT (75% among PSC patients and 68% among non-PSC patients). Mean age at cancer diagnosis was 57 years (49 years among PSC patients and 60 years among non-PSC patients). Only 6 (18%) cases were diagnosed before age 50, of which 5 were PSC patients.
F I G U R E 1 Cumulative incidence of (A) all posttransplant cancers and separately for (B) all cancers except nonmelanoma skin cancer (NMSC), accounting for competing mortality 
| Multivariate analysis
In multivariate Cox regression analysis, factors independently associated with any cancer were higher age, LT before year 2000, LT in
Finland or Denmark, and alcoholic liver disease ( Table 4 ). The same factors remained significant in a separate analysis that considered any cancer except nonmelanoma skin cancer as the outcome (Table 4) .
Type of calcineurin inhibitor, type of antimetabolite, and steroid use were not significant in either analysis; however, the drug data were available for the first month only. By Cox regression analysis adjusted for age and gender, LT after year 2000 was associated with a reduced risk for nonmelanoma skin cancer (hazard ratio 0.48, 95% CI, 0.31%-0.75%) and non-Hodgkin lymphoma (hazard ratio 0.63, 95% CI 0.35%-1.14%), as compared to LT in the 1980s or 1990s.
| DISCUSSION
We observed a decrease over time in posttransplant cancer incidence relative to the general population. This was observed across gender, age-, and LT indication groups. Moreover, a decrease in cancer risk was observed in particular for nonmelanoma skin cancer and non-Hodgkin lymphoma, both of which are strongly linked to immunosuppression.
SIRs generally decrease along with increasing age as cancer incidence rises with age in the general population, and average age at transplantation increased over time. Although this may contribute to the observed decrease in SIRs over time, our subgroup analyses by age and multivariate analysis confirmed that the absolute cancer incidence among LT patients was declining with decade of transplantation independently of age. This verifies that the reduction in posttransplant cancer risk is true, and not just explained by changes in age structure.
Although the study methodology constrains us from making conclusions on possible causes for this decrease, based on our multivariate analysis, the gradual shift over time from cyclosporine to tacrolimus or from azathioprine to mycophenolate seems not to be the cause.
We observed no effect of type of immunosuppression on the overall cancer risk. However, these findings are limited by the fact that we could only include the first-month medication, and data were missing for 21% of subjects. Calcineurin-inhibitor trough levels have been associated with posttransplant cancer risk. 26, 27 It can be speculated that these trough level targets have progressively decreased over time, but we were unable to verify this in the present cohort.
All the changes in immunosuppression policy such as introduction of new drugs, which can at least partly be seen in Table 1 , and the progressive reduction in calcineurin inhibitor exposure have occurred in various Nordic centers at different time points and often first in specific subgroups of patients. Even now the immunosuppression policies vary slightly between the 5 centers. Therefore, it was practically impossible to divide the study cohort according to clear fixed-year milestones in order to prove the effects of immunosuppression reduction.
Although the incidence of cancer decreased over time, no significant change was observed in cancer mortality in a recent Nordic study comparing cancer mortality of LT patients to that of the general population. 2 It is possible that cancers are still detected at more advanced stages, thus leading to high mortality despite improved treatment efforts. 13, 14 The overall SIR in the present study was 2.22, and with nonmelanoma skin cancer excluded, 1.69. These SIRs are similar to those in earlier population-based studies from the United Kingdom (overall SIR excluding nonmelanoma skin cancer, 2. Liver cancers registered within 6 mo from LT excluded (liver and all sites). Biliary cancer registered within 6 mo excluded from PSC patients. Missing SIRs mean that there were no observed cases. CIs, confidence intervals; LT, liver transplantation; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
a Only cancers observed within 10 y from LT included, in order to adjust for different follow-up times. *P < .05.
T A B L E 3 (Continued) skin cancers in the overall SIR, length of follow-up, inclusion of pediatric patients, patient demographic factors, and cancer incidences in the background population (affected also by the completeness of cancer registries).
Our 10-year cumulative cancer incidence (11%) was within the range reported in single-center studies (7%-21%). [31] [32] [33] To our knowledge, only 1 previous study reported 20-year cumulative cancerincidence rates, 15.7%, 31 which was slightly lower than that in our study (22%). However, the cumulative incidence rates of different studies are not directly comparable because of varying age structure of the person-years at follow-up.
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In line with a recent meta-analysis, 35 non-PSC patients exhibited no significantly increased risk for colorectal cancer, a finding that may have implications for colonoscopy screening in the LT population.
However, the issue remains controversial, 13, 36 and other risk factors for colorectal cancer have not been adjusted for sufficiently in either the present or previous studies to recommend standard population screening protocols for non-PSC LT patients.
Among PSC patients, we observed a 4-fold risk for colorectal cancer post-LT, and this risk was elevated already within 10 years from LT despite routine screening colonoscopy pretransplant for such patients. Furthermore, this represents an underestimate, because up was also found in the study of Koshiol et al, the SIR being 2.9 for all as compared to 4.6 in the present study, and for PSC patients the SIR was as high as 21.
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Alcoholic cirrhosis patients may have concomitant chronic pancreatitis-like lesions, which might be a source for the elevated pancreas cancer risk in this group. The risk for pancreas cancer was recently found to be elevated also among alcoholic liver disease patients who have not been transplanted. 45 The slightly higher SIR for pancreas cancer in the present study may be related to the elevated SIRs of these subgroups, especially as PSC is one of the main indications for LT in the Nordic countries. As compared to other solid organ transplantations, LT patients seem to have slightly higher incidence of pancreatic cancer than kidney 28, 46 or heart and lung 20 transplantation patients.
Major strengths of our study include the completeness of data in the Nordic LT registry and the national cancer registries, and the unique ability to combine data from several countries. All Nordic LT patients were included (no patient exclusions), and each patient could be successfully linked with cancer-registry data. The NORDCAN classification system, adapted by the cancer registries in all Nordic countries, allows for straightforward combination of data across countries.
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The proportion of hepatitis C and alcoholic cirrhosis was lower, and PSC higher, in the present patient cohort compared to the cohorts of other countries; however, subgroup analyses by LT indication were performed to account for this.
Study limitations include the lack of certain relevant variables such as immunosuppression protocols and calcineurin-inhibitor trough levels. In addition, the cancer screening has varied within and between each center, not to mention development of surveillance and therapy over time. Medication, patient performance state, smoking status, and family cancer history were not recorded. The number of LT patients operated on in the 1980s was small.
The Nordic LT cohort includes more PSC patients compared to many other countries. Subgroup analyses by etiology were performed to account for this.
In conclusion, we observed a decrease over time in the cancer incidence after LT relative to the general population. This emerges as positive news for the transplant community. Although the exact causes for this improvement remain unclear, improved patient management, increased focus on long-term complications, cancer surveillance protocols, and more judicious immunosuppression regimens are likely factors.
